Untargeted Metabolomic Study for Urinary Characterization of Adult Patients with Phenylketonuria.

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by phenylalanine hydroxylase deficiency, leading to phenylalanine (Phe) accumulation and neurological dysfunction if untreated. While metabolomics holds promise for biomarker discovery in PKU, few studies have examined urinary metab...

Descripción completa

Detalles Bibliográficos
Autores: García Villoria, Judit, González-Rodríguez, Arnau, Barrau Martínez, Blanca, Pané, Adriana, López Galera, Rosa Ma., Tobias, Ester, Montserrat-Carbonell, Cristina, Guitart Mampel, Mariona, Jáuregui Pallarés, Olga, Roca-Vives, Regina, Milisenda, José, Matas García, Ana, Forga Visa, María De Talló, Moreno Lozano, Pedro Juan, Garrabou Tornos, Glòria, Urpí Sardà, Mireia, Llorach, Rafael, Consortium PKU.cat
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/225683
Acceso en línea:https://hdl.handle.net/2445/225683
Access Level:acceso abierto
Palabra clave:Fenilcetonúria
Metabolòmica
Orina
Espectrometria de masses
Phenylketonuria
Metabolomics
Urine
Mass spectrometry
Descripción
Sumario:Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by phenylalanine hydroxylase deficiency, leading to phenylalanine (Phe) accumulation and neurological dysfunction if untreated. While metabolomics holds promise for biomarker discovery in PKU, few studies have examined urinary metabolites using untargeted approaches. This study applied untargeted metabolomics using HPLC-QTOF-MS to analyze urine from 36 adult patients with PKU and 34 healthy controls. Biomarker Analysis was performed with MetaboAnalyst 6.0. A total of 73 significant metabolites (FDR < 0.05; VIP > 1) were identified, with 29 upregulated and 44 downregulated in PKU. A 23% of these metabolites were related to Phe metabolism, while 77% were associated with alterations across more than 10 metabolic pathways, including leucine and tryptophan metabolism, acylcarnitines, vitamins, and diet- or microbiota-derived compounds, among others. Specifically, upregulated metabolites with an AUC > 0.9 included several Phe-derived compounds, the nucleoside 8-hydroxy-7-methylguanine, and indole compounds (1H-indole-3-carboxaldehyde). Conversely, downregulated metabolites with an AUC > 0.9 included N-acetyl(iso)leucine and a heptenoylcarnitine isomer. The Random Forest-based model demonstrated enhanced predictive performance when integrating 10 metabolites, supporting their potential utility as biomarkers for PKU. These findings improve the biological understanding of metabolic disturbances beyond Phe, and may support the development of new therapeutic and dietary strategies.